B cell or T cell-dominant recurrence after rituximab therapy in patients with SLE

Annals of the Rheumatic Diseases

Volumn 71, Issue 10, 2012, Pages 1749-1750

  Iwata, Shigeru ^a   Saito, Kazuyoshi ^a   Tokunaga, Mikiko ^a   Tanaka, Yoshiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD19 ANTIGEN; CD69 ANTIGEN; CELL NUCLEUS ANTIGEN; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN D ANTIBODY; INDUCIBLE T CELL COSTIMULATOR; RITUXIMAB; TACROLIMUS;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; B LYMPHOCYTE; CASE REPORT; CD4+ T LYMPHOCYTE; CELL ACTIVATION; CELL COUNT; CELL SURVIVAL; CLINICAL FEATURE; DISEASE CONTROL; DISEASE DURATION; DOWN REGULATION; DRUG MECHANISM; DRUG PULSE THERAPY; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNE DEFICIENCY; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; MEMORY CELL; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; REMISSION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RECURRENCE; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84866114867     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-201317     Document Type: Letter

References (10)

1. Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9. (Pubitemid 39062719)
2. Leandro MJ, Edwards JC, Cambridge G, et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7. (Pubitemid 36118931)
3. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503. (Pubitemid 38316738)
4. Anolik J, Sanz I, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep 2003;5:350-6.
5. Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007;17:191-7. (Pubitemid 46929903)
6. Tokunaga M, Fujii K, Saito K, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) 2005;44:176-82. (Pubitemid 40277398)
7. Tokunaga M, Saito K, Kawabata D, et al. Ef ficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-5. (Pubitemid 46580466)
8. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
9. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56. (Pubitemid 47502752)
10. Iwata S, Saito K, Tokunaga M, et al. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol 2011;38:633-41.